Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.12)
# 464
Out of 5,241 analysts
98
Total ratings
49.3%
Success rate
16.01%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTC Benitec Biopharma | Initiates: Outperform | $25 | $11.49 | +117.58% | 1 | May 12, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $125 → $130 | $66.13 | +96.58% | 5 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $110 → $120 | $51.81 | +131.62% | 13 | May 5, 2026 | |
| MRNA Moderna | Maintains: In-Line | $35 → $50 | $49.04 | +1.96% | 8 | May 4, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $140 → $200 | $145.66 | +37.31% | 1 | Apr 14, 2026 | |
| UPB Upstream Bio | Downgrades: In-Line | $40 → $15 | $9.09 | +65.02% | 2 | Mar 27, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $30 → $45 | $33.09 | +35.99% | 3 | Feb 27, 2026 | |
| VIR Vir Biotechnology | Maintains: Outperform | $12 → $18 | $8.79 | +104.78% | 2 | Feb 24, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $698.25 | +25.31% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $20.88 | +91.57% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $18.34 | +199.89% | 1 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $27.93 | +25.31% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $8.15 | +206.75% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $80 | $75.85 | +5.47% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $16.87 | +101.54% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $54.39 | +1.12% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $158.42 | +16.78% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $89.55 | +39.59% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $25.00 | +252.00% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $192.95 | +43.04% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.07 | +1,040.07% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $326.31 | -28.90% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $95.31 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $129.58 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $37.48 | -43.97% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.92 | +232.37% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $2.23 | +348.43% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $21.71 | - | 5 | Feb 14, 2018 |
Benitec Biopharma
May 12, 2026
Initiates: Outperform
Price Target: $25
Current: $11.49
Upside: +117.58%
BridgeBio Pharma
May 8, 2026
Maintains: Outperform
Price Target: $125 → $130
Current: $66.13
Upside: +96.58%
BioMarin Pharmaceutical
May 5, 2026
Maintains: Outperform
Price Target: $110 → $120
Current: $51.81
Upside: +131.62%
Moderna
May 4, 2026
Maintains: In-Line
Price Target: $35 → $50
Current: $49.04
Upside: +1.96%
Revolution Medicines
Apr 14, 2026
Maintains: Outperform
Price Target: $140 → $200
Current: $145.66
Upside: +37.31%
Upstream Bio
Mar 27, 2026
Downgrades: In-Line
Price Target: $40 → $15
Current: $9.09
Upside: +65.02%
Edgewise Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $30 → $45
Current: $33.09
Upside: +35.99%
Vir Biotechnology
Feb 24, 2026
Maintains: Outperform
Price Target: $12 → $18
Current: $8.79
Upside: +104.78%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $698.25
Upside: +25.31%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $20.88
Upside: +91.57%
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $18.34
Upside: +199.89%
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $27.93
Upside: +25.31%
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $8.15
Upside: +206.75%
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $75.85
Upside: +5.47%
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $16.87
Upside: +101.54%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $54.39
Upside: +1.12%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $158.42
Upside: +16.78%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $89.55
Upside: +39.59%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $25.00
Upside: +252.00%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $192.95
Upside: +43.04%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.07
Upside: +1,040.07%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $326.31
Upside: -28.90%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $95.31
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $129.58
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $37.48
Upside: -43.97%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.92
Upside: +232.37%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $2.23
Upside: +348.43%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $21.71
Upside: -